Dr. Mdluli joined the TB Alliance R&D team in May as the Project Leader of Research, working closely with Dr. Zhenkun Ma, Head of Research. Dr. Mdluli brings over 10 years of drug discovery expertise, particularly in assay development and high throughput screening, to help build and advance the TB Alliance’s portfolio.
“We are pleased to have Khisi join us. He brings a deep knowledge of the biology of the disease essential to guiding our discovery programs, such as the target-based projects in our GSK partnership, and identifying the latest science in order to sustain the portfolio,” said Dr. Mel Spigelman, R&D Director.
A native of Swaziland, Dr. Mdluli is a highly regarded expert in the microbiology, molecular biology and biochemistry of Mycobacterium tuberculosis. A three-year visiting fellowship at the U.S. National Institutes of Health resulted in several important publications describing the mechanism of action of two currently used drugs, including isoniazid. Dr. Mdluli also spent two years at Cumbre Inc., a Texas based biotech, and six years at Chiron Corporation as a Senior Scientist where he helped establish and manage a major antimicrobial discovery program.